Abstract: The present disclosure relates to a composition comprising a carnosine-magnesium complex. The composition is designed to be applied to the skin and causes an increase in carnosine levels in the body. The topical 5 composition comprising a carnosine-magnesium complex has the effect of improving an athlete's physical performance and may be effective for the treatment of a variety of medical conditions. Also disclosed is a method for preparing the carnosine-magnesium complex.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
April 13, 2021
Inventors:
Chad Macias, Tim Sharpe, Massimo Ferrari
Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or more other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.
Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
Abstract: Hydrogels and hybrid hydrogels, methods of making the hydrogels/hybrid hydrogels, and methods of using the hydrogels/hybrid hydrogels. The hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties). The hybrid hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties) and poly(ester amide) moieties. The poly(ester amide) moieties can have one or more arginine moieties. The hydrogels/hybrid hydrogels can be used, for example, in consumer products and as cargo carrier materials (e.g., as therapeutic agent carriers).
Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Type:
Grant
Filed:
October 25, 2013
Date of Patent:
February 16, 2021
Assignee:
Teikoku Pharma USA, Inc.
Inventors:
Richard D. Hamlin, Amit Jain, Jianye Wen
Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.
Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.
Type:
Grant
Filed:
October 27, 2016
Date of Patent:
February 9, 2021
Assignee:
KEMIN INDUSTRIES, INC.
Inventors:
Geoffrey Paul Horst, Robert Bernard Levine
Abstract: A hydrogel comprising a colloidal suspension of MIXMIIYPZ two-dimensional nanocrystals in water, wherein MI is Na+ and/or Li+, MII is Mg2+ or a mixture of Mg2+ with one or more Ni2+, Zn2+, Cu2+, Fe2+ and/or Mn2+, P is a mixture of dibasic phosphate ions (HPO42?) and tribasic phosphate ions (PO43?), X ranges from about 0.43 to about 0.63, Y ranges from about 0.10 to about 0.18, Z ranges from about 0.29 to about 0.48, X, Y, Z being mole fractions, is provided.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
December 29, 2020
Assignee:
INVICARE INC.
Inventors:
Faleh Tamimi Marino, Ashwaq Ali Al-Hashedi, Marco Laurenti, Ahmed Ebraheem Al Subaie, Mohamed-Nur Abdallah, Iskandar Tamimi Marino
Abstract: A personal care formulation comprising an active compound is operable to reduce the surface friction of hair fibres and promoting inter-fibre movement. The active compound is the reaction product of a fatty acid and a polyamine. The use of the active compound in a personal care formulation works as a friction modifier operable to reduce the surface friction of hair fibres. The invention extends to the active compound and a method of reducing hair-fibre surface friction.
Type:
Grant
Filed:
July 3, 2012
Date of Patent:
December 1, 2020
Assignee:
Croda International Plc
Inventors:
Michael Christopher Hindley, David John Freeman, James Prodger, Sean Philip Nigel Rouse
Abstract: This disclosure relates to hair styling compositions and processes, and more particularly to compositions for disentangling or crosslinking hair that are useful in hair styling processes.
Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
Abstract: Provided are core-shell particles which are kept stable in a solvent such as water for a long period. Each core-shell particle includes a core which contains a hydrophobic polymer having an anionic group and a shell which contains calcium phosphate. At least one of calcium atoms contained in calcium phosphate is chemically bonded to a functional group derived from the anionic group. In a method of manufacturing core-shell particles each core-shell particle includes a core which contains a hydrophobic polymer and a shell which contains calcium phosphate, the method includes the steps of: mixing a water-soluble organic solution which contains a hydrophobic polymer having an anionic group with a solution which contains calcium ion so as to obtain a first mixed solution; mixing the first mixed solution with a solution which contains phosphate ions so as to obtain a second mixed solution; and stirring the second mixed solution.
Type:
Grant
Filed:
August 31, 2015
Date of Patent:
August 25, 2020
Assignee:
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
Abstract: The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer.
Type:
Grant
Filed:
May 2, 2008
Date of Patent:
July 21, 2020
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Nika N. Danial, Loren D. Walensky, Gregory Bird, Susan R. Korsmeyer
Abstract: A non-aqueous composition and method for reducing the drying time of wet hair includes applying added water to human hair to obtain wet hair and applying a nonaqueous serum comprising a combination of about 55 to about 65 percent by weight of at least one volatile silicone compound, about 30 to about 40 percent by weight of at least one high molecular weight silicone elastomer, a thermoprotective agent, an emollient, and a conditioning agent; applying the nonaqueous serum and heat to the wet hair in order to remove from about 80% to about 100% of the added water. In one embodiment, the application of the serum is capable of reducing a drying time of the wet hair by at least 25 percent.
Abstract: An antithrombogenic metallic material includes a metallic material whose surface is coated with a coating material, the coating material containing: a phosphonic acid derivative or a catechol derivative; a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; the polymer being covalently bound to the phosphonic acid derivative or the catechol derivative, the phosphonic acid derivative or the catechol derivative being bound to the metallic material through a phosphonic acid group or a catechol group thereof, wherein the abundance ratio of nitrogen atoms to the abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on the surface is 4.0 to 13.0 atomic percent.
Type:
Grant
Filed:
March 31, 2016
Date of Patent:
July 14, 2020
Assignee:
Toray Industries, Inc.
Inventors:
Koji Kadowaki, Masaki Fujita, Yuka Sakaguchi, Kazuhiro Tanahashi
Abstract: The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
July 7, 2020
Assignee:
GNOSIS SPA
Inventors:
Daniele Giovannone, Niccolò Miraglia, Marco Berna
Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Type:
Grant
Filed:
March 8, 2018
Date of Patent:
May 5, 2020
Assignee:
Pfizer Inc.
Inventors:
Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock